Alpelisib (Pivikto) is an alpha-specific class I phosphatidylinositol-3-kinase (PIK3CA) inhibitor indicated for the treatment of postmenopausal women, and men, with hormone receptor positive, HER2-negative, advanced breast cancer with a PIK3CA mutation in combination with fulvestrant after disease progression following an endocrine-based regimen.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
